Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus

References

• UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837–53
   Google Scholar
• Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomised prospective 6-year study. Diabetes Res Clin Pract 1995;28: 103–17
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SC, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). Br Med J 2000;321: 405–12
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulphonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). J Am Med Assoc 1999;281:2005–12
   PubMed Web of Science ®Google Scholar
• Barnett AH. Insulin-sensitizing agents – thiazolidindiones (glita-zones). Curr Med Res Opin 2002;18(Suppl 1):31–9
   Google Scholar
• Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996;39:665–8
   PubMed Web of Science ®Google Scholar
• Otto C, Lehke M, Göke B. Novel insulin sensitizers: pharmacogenomic aspects. Pharmacogenomics 2002;3:1–18
   PubMedGoogle Scholar
• Baba S. Pioglitazone: a review of Japanese clinical studies. Curr Med Res Opin 2001;17:166–89
   PubMed Web of Science ®Google Scholar
• Göke B. Coefficient of β-cell failure in patients with type 2 diabetes treated with pioglitazone or acarbose. Exp Clin Endocrinol Diabetes 2003;in press
   Google Scholar
• Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002;25:707–11
   Google Scholar
• LaCivita KA, Villerreal G. Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone. Curr Med Res Opin 2002;18:363–70
   PubMed Web of Science ®Google Scholar
• Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL, on behalf of the Pioglitazone 001 Study Group. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month, randomized, placebo-controlled, dose-response study. Diabetes Care 2000;23: 1605–11
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Goke B. Combining pioglitazone with a sulphonylurea or metformin in the management of type 2 diabetes. Exp Clin Endocrinol Diabetes 2000;108:256–66
   Google Scholar
• Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 1 diabetes. Diabetes Care 2002;25: 517–23
   PubMed Web of Science ®Google Scholar
• Kaneko T, Baba S, Toyota T. Dose-finding study of AD-4833 in patients with NIDDM on diet therapy alone: double-blind, comparative study on four dosages. Jpn J Clin Exp Med 1997;74: 1250–77
   Google Scholar
• Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S, Pioglitazone 014 Study Group. Efficacy and safety of pioglita-zone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002;56: 251–7
   Google Scholar
• Göke B, on behalf of the German Pioglitazone Study Group. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. Treatments Endocrinol 2002;1:329–36
   Google Scholar
• Goldstein BJ, Cobitz AR, Hand LM, Chen H. Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control? Curr Med Res Opin 2003;19:192–9
   PubMed Web of Science ®Google Scholar
• King AB, Armstrong DU. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review. Diabetes Technol Ther 2002;4:145–51
   PubMedGoogle Scholar
• Fullert S, Schneider F, Haake E, Rau H, Badenhoop K, Lubben G, Usadel K-H, Konrad T. Effects of pioglitazone in non-diabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2002;87:5503–6
   PubMed Web of Science ®Google Scholar
• Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Br Med J 2000;321: 412–19
   PubMed Web of Science ®Google Scholar
• Martin G, Schoonjans K, Staels B, Auwerx J. PPAR-gamma activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis 1998;137(Suppl.):S75–80
   Google Scholar
• Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nature Med 2002;8:1122–8
   PubMed Web of Science ®Google Scholar
• Heymsfield SB, Allison DB, Wang Z-M. Evaluation of total and regional body composition. In: Bray GA, Bouchard C, James WPT, eds. Handbook of Obesity. New York: Marcel Dekker; 1998:41–77
   Google Scholar
• Gastaldelli A, Miyazaki Y, Pettiti M, Matsuda M, Mahankali S, Santini E, DeFronzo RA, Ferrannini E. Metabolic effects of visceral fat accumulation in type 2 diabetes. J Clin Endocrinol Metab 2002;87:5098–103
   Web of Science ®Google Scholar
• Lebovitz HE. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002;18:S23–9
   PubMed Web of Science ®Google Scholar
• Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373–9
   PubMed Web of Science ®Google Scholar